S. Ashley
Institute of Cancer Research · 12 works · 580 citations · h-index 7
Top works
- Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer
- Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
- A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer
- Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.
- A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer
- Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer.
- [Double-blind trial of oral clodronate in breast cancer patients with bone metastases].
- Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer
- THE EFFECT OF PERFORMANCE STATUS ON SURVIVAL
- Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor in patients with advanced breast cancer
- 57 Mitoxantrone and methotrexate (2M), a new chemotherapy regimen for breast cancer that can be safely combined with tamoxifen
- Abstract P6-11-11: Trastuzumab beyond Progression in HER2-Positive Advanced Breast Cancer: The Royal Marsden Experience